Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed financial performance with reduced losses but declining cash reserves and increased SG&A expenses. Strategic partnerships are still in discussion, delaying revenue generation. The Q&A section highlights potential risks, such as supply chain readiness and financing challenges. Despite some positive developments like improved EPS and reduced R&D expenses, the overall sentiment is negative due to financial health concerns and lack of finalized partnerships.
KNW Transcript
Earnings call transcript: Know Labs Q1 2025 widens net loss, plans expansion
Unknown2-14
The earnings call reveals significant challenges: a net loss increase, negative shareholder equity, and potential delisting. Although cost management has improved, financial risks and capital raising issues overshadow positives. The Q&A section highlights unclear management responses, particularly concerning the KTL program and equity issues. The absence of shareholder return initiatives further dampens sentiment. Given these factors, a negative stock price reaction is likely.
Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript
Neutral8-15
Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript
Unknown5-16
The earnings call reveals a mixed financial performance with reduced losses but declining cash reserves and increased SG&A expenses. Strategic partnerships are still in discussion, delaying revenue generation. The Q&A section highlights potential risks, such as supply chain readiness and financing challenges. Despite some positive developments like improved EPS and reduced R&D expenses, the overall sentiment is negative due to financial health concerns and lack of finalized partnerships.
Know Labs, Inc. (KNW) Q4 2023 Earnings Call Transcript
Unknown12-19
The earnings call highlights several concerns: regulatory uncertainty, financial constraints, and competitive pressures. While there is a decrease in net loss, the company still faces a significant cash burn and operational challenges. The public offering at a low share price indicates financial distress. Unclear timelines for strategic collaborations and FDA approval add to the uncertainty. Despite some positive developments, the overall sentiment is negative due to these risks and the lack of clear guidance.
KNW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
